Zobrazeno 1 - 10 of 18 pro vyhledávání: '"J. C. Cappelleri"'
1
Akademický článek
Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire
Autor: L. C. Coates, A.-M. Orbai, V. F. Azevedo, J. C. Cappelleri, K. Steinberg, R. Lippe, I. Lim, L. Eder, P. Richette, M. Y. Weng, R. Queiro Silva, L. Fallon
Publikováno v: Health and Quality of Life Outcomes, Vol 18, Iss 1, Pp 1-10 (2020)
Abstract Background Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory musculoskeletal disease, manifesting as peripheral arthritis, enthesitis, dactylitis, spondylitis, and skin and nail psoriasis. A core set of domains for measurin
Externí odkaz: https://doaj.org/article/aa0cb69614bc48d696e133196bea7757
Zobrazit plný text záznamu
2
P186 Impact of tofacitinib maintenance therapy on key Ulcerative Colitis patient-reported outcomes of fatigue, urgency, abdominal pain and sexual dysfunction using IBDQ and SF-36 individual items as proxies
Autor: M C Dubinsky, S Gardiner, P Hur, X Guo, J Paulissen, J C Cappelleri, A G Bushmakin, J Panés
Publikováno v: Journal of Crohn's and Colitis. 17:i339-i342
Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). This novel analysis evaluated tofacitinib outcomes using items from the Inflammatory Bowel Disease Questionnaire-32 (IBDQ) and Short
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::001ae9458bcd35c15719e7aef7dba6de
https://doi.org/10.1093/ecco-jcc/jjac190.0316
Zobrazit plný text záznamu
3
Physician and patient perceptions of surgical procedures for osteoarthritis of the knee in the United States, Europe, and Japan: results of a real-world study
Autor: N, Fukui, P G, Conaghan, K, Togo, N, Ebata, L, Abraham, J, Jackson, M, Berry, J C, Cappelleri, H, Pandit
Publikováno v: BMC musculoskeletal disorders. 23(1)
Osteoarthritis (OA) is the most common form of arthritis, with the knee being the joint most frequently affected, and symptomatic knee OA affecting around one quarter of the general population. For patients who do not respond to non-pharmacologic or
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c5b8542afbf386c65fe120fdead02fce
https://pubmed.ncbi.nlm.nih.gov/36471384
Zobrazit plný text záznamu
4
AB0750 Back pain and morning stiffness as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
Autor: L. E. Kristensen, P. C. Taylor, V. Navarro-Compán, M. Magrey, J. C. Cappelleri, A. G. Bushmakin, A. Yndestad, O. Dina
Publikováno v: Annals of the Rheumatic Diseases. 81:1500.1-1500
BackgroundFatigue is a prevalent symptom of ankylosing spondylitis (AS)1 and can contribute to higher levels of disease, disability and poor health-related quality of life.2 Back pain and morning stiffness are also commonly reported symptoms.3 Tofaci
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::85f2a4e75cb26141b02794f43b25cc3d
https://doi.org/10.1136/annrheumdis-2022-eular.28
Zobrazit plný text záznamu
5
POS0305 TIME TO IMPROVEMENT OF FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN A STUDY OF TOFACITINIB
Autor: L. Gossec, D. Cella, J. A. Walsh, R. Sengupta, A. G. Bushmakin, J. C. Cappelleri, A. Yndestad, O. Dina
Publikováno v: Annals of the Rheumatic Diseases. 81:401.1-402
BackgroundFatigue is common in patients (pts) with ankylosing spondylitis (AS) and is associated with higher levels of pain and functional disability.1 Tofacitinib is an oral JAK inhibitor approved for the treatment of AS. In pts with AS, greater imp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc2408833d50cac6ace10b59377e9ebb
https://doi.org/10.1136/annrheumdis-2022-eular.2391
Zobrazit plný text záznamu
8
Additional file 3 of Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire
Autor: Coates, L. C., A.-M. Orbai, V. F. Azevedo, J. C. Cappelleri, K. Steinberg, R. Lippe, I. Lim, L. Eder, P. Richette, M. Y. Weng, R. Queiro Silva, L. Fallon
Additional file 3: Supplementary Figure 1. Patient-reported impact of PsA on work. Data represent the percentage of responders using the weighted base of each country in Table 1. Data are reported in response to the question, “Have you done any of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0866160c19b0645177f54076fdf91887
Zobrazit plný text záznamu
10
Evaluation of the fibromyalgia impact questionnaire at baseline as a predictor for time to pain improvement in two clinical trials of pregabalin
Autor: A G, Bushmakin, J C, Cappelleri, A B, Chandran, G, Zlateva
Publikováno v: International journal of clinical practice. 67(1)
The Fibromyalgia Impact Questionnaire (FIQ) is a patient-reported outcome that evaluates the impact of fibromyalgia (FM) on daily life. This study evaluated the relationships between the functional status of FM patients, measured with the FIQ at base
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::30710fc6fb9f3807d36d48f8ad80df3c
https://pubmed.ncbi.nlm.nih.gov/23241048
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje